so basically the formastanz label must be inaccurate since you got little to no effect at what would equate to 150mg formestane with the FS (15 pumps should equal 150mg formestane), like REALLY inaccurate lol....or its not what its labeled as. I still have 2 bottles FS from a recent sale, was gonna try formeron next, but will run through these first.
Other differences between Formeron and the FS=
Our carrier is superior.
ours is 7$ less for the same amount of formestane per bottle.
2pumps = 150mg whereas it takes 15 pumps of the competitor.
Ours does not contain potential tumor or cancer causing agents and theirs does.
7,8 benzoflavone is also known as alpha naphthoflavone.
Its been shown to be carcinogenic in other studies as well. IM not gonna dig em all up but they are there. Here is one for you.
Am J Pathol. 1991 Sep;139(3):669-79.
Comparative morphologic and immunohistochemical studies of estrogen plus alpha-naphthoflavone-induced liver tumors in Syrian hamsters and rats.
Oberley TD,
Slattery AF,
Gonzalez A,
Li SA,
Li JJ.
Source
Pathology Service, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705.
Abstract
Syrian hamsters were treated with ethinylestradiol and maintained on a diet containing alpha-naphthoflavone (alpha NF), a regimen that produces a high incidence of liver tumors. Morphologic analyses (light microscopy, immunoperoxidase studies, and electron microscopy) were performed on livers of these animals. After 4 months of hormone plus alpha NF treatment, marked hepatocyte cell changes were already present, as demonstrated by loss of eosinophilic staining of hepatocyte cytoplasm. Large multinucleated hepatocytes exhibiting frequent mitoses were observed around central veins. After 5 months of treatment, there was proliferation of bile ducts, and small cells with eosinophilic cytoplasm resembling hepatocytes appeared surrounding these bile ducts. At 7 to 8 months, the first tumor nodules (foci) were seen. Tumor foci in the portal area consisted of small clusters of large cells resembling hepatocytes with irregular nuclei. At the same time, dysplastic glands were identified among proliferating bile ducts. By 8 to 10 months, large tumors were present. These were trabecular hepatocellular carcinomas with widely varying individual cell morphology. Compared with adjacent liver, dysplastic glands in the portal areas, microcarcinomas, and large tumors all showed intense immunostaining for cytokeratin. Rats treated with the same regimen also developed hepatic tumors, but the light and electron microscopy results and immunohistochemical profiles were very different. Altered hepatic foci composed of small hepatocytes were typically prominent; however, malignant tumors did not arise from the portal area. Neither altered foci nor tumors stained significantly for cytokeratin. These data suggest that the biochemical events giving rise to these liver tumors differ between the species studied, despite the animals being exposed to the same treatment regimens.
PMID:1887866 [PubMed - indexed for MEDLINE]
PMCID
MC1886233
Free PMC Article